VolitionRx Limited issued shares of common stock to Lind Global Asset Management XII LLC to satisfy conversion obligations under senior secured convertible promissory notes. On September 2, 2026, the company issued 706,214 shares to settle a $250,000 obligation, and on September 10, 2026, it issued 707,236 shares to satisfy a $215,000 obligation. As of September 14, 2026, there were 27,903,326 shares of common stock issued and outstanding. VolitionRx Limited operates in the healthcare diagnostics industry, developing molecular diagnostic tests for cancer detection.

VolitionRx Limited prepaid in cash approximately $422,000 on September 11, 2026, satisfying the outstanding balance of its senior secured convertible promissory note originally issued for $7,500,000 to Lind Global Asset Management XII LLC. This early retirement eliminates potential future equity dilution associated with the conversion of the 2025 Note. The company's second note to Lind, originally $2,400,000, remains outstanding with a balance of approximately $2,041,667. VolitionRx Limited is a multinational epigenetics company developing and commercializing blood tests for early disease detection and monitoring.

VolitionRx Limited entered into a Waiver and Consent with Lind Global Asset Management XII LLC on September 2, 2026. This agreement waives covenant breaches related to the Company's At-The-Market (ATM) sales exceeding the $10 million annual cap under its Securities Purchase Agreement dated May 15, 2025. Lind consented to treat ATM sales in excess of the limit as Permitted ATM Sales and waived remedies for Events of Default triggered by these sales. The waiver also adjusts the conversion price of the senior secured convertible promissory notes ($9.9 million total principal) and exercise prices of associated warrants based on ATM sales through August 28, 2026. VolitionRx Limited operates in the healthcare diagnostics industry, developing molecular diagnostic tests for cancer detection.

VolitionRx Limited issued a total of 4,778,728 shares of common stock to Lind Global Asset Management XII LLC between August 27 and August 31, 2026. These issuances satisfied conversion obligations totaling $1,715,000 under senior secured convertible promissory notes originally issued in May 2025. The transactions were conducted pursuant to a securities purchase agreement and relied on exemptions from registration under Section 4(a)(2) of the Securities Act or Regulation D. VolitionRx Limited operates in the healthcare diagnostics industry, developing molecular diagnostic tests for cancer detection.

VolitionRx Limited reported financial results for the quarter ended June 30, 2026. First-half revenue reached $1.4 million, a 112% increase year-over-year, while second-quarter revenue was approximately $0.4 million. Operating expenses decreased by 32%, resulting in an operating loss of $4.2 million, down 34% from the prior year period. The company raised $5.3 million through equity financing activities during the quarter, including $1.2 million from its at-the-market facility and $4.1 million from a public offering of shares and warrants. Management highlighted ongoing licensing discussions with diagnostic companies and progress on clinical submissions for its Nu.Q platform. VolitionRx Limited is an epigenetics company developing blood-based diagnostic tests for cancer and other diseases.

VolitionRx Limited issued a total of 779,371 shares of common stock to Lind Global Asset Management XII LLC between July and August 2026. These issuances satisfied payment obligations totaling $750,000 associated with senior secured convertible promissory notes originally issued under a securities purchase agreement dated May 15, 2025. The transactions were conducted in reliance on private placement exemptions and involved no paid commissions or public solicitation. VolitionRx Limited operates in the healthcare diagnostics industry, developing molecular diagnostic tests for cancer detection.